Table 4 Summary for failure of clinical trials for tremelimumab [36]

Advanced melanoma

Monotherapy

Phase IIb

A3671009

https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-reports-results-from-the-arctic-trial-in-third-line-non-small-cell-lung-cancer-24042018.html

Mesothelioma

Monotherapy

Phase IIb

DETERMINE

https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-provides-update-on-the-phase-iii-mystic-trial-of-imfinzi-and-tremelimumab-in-stage-iv-non-small-cell-lung-cancer16112018.html

Previously treated NSCLC

Durvalumab plus tremelimumab

Phase III

ARCTIC

http://www.pharmabiz.com/NewsDetails.aspx?aid = 112740&sid = 2

Previously untreated NSCLC

Durvalumab plus tremelimumab

Phase III

MYSTIC

https://www.marketscreener.com/ASTRAZENECA-4000930/news/AstraZeneca-Update-on-the-Phase-III-NEPTUNE-trial-29093768/

HNSCC

Durvalumab plus tremelimumab

Phase III

EAGLE

[37]

Previously untreated NSCLC with high TMB

Durvalumab plus tremelimumab

Phase III

NEPTUNE

[38]